Abstract Details

Title Rates of Discontinuation and Nonpublication in Glioma Clinical Trials

Topic Neuro-oncology

Presentation(s) P3 - Poster Session 3 (11:45 AM-12:45 PM)

Poster/Presentation
Number 6-002

Objective This study aims to analyze the rates of discontinuation and nonpublication in clinical trials related to gliomas, highlighting factors that contribute to these issues.

Background Gliomas are complex tumors that present significant challenges in research and treatment. Despite numerous clinical trials, a substantial number are discontinued or unpublished, impacting the overall knowledge base and treatment strategies for glioma patients.

Design/Methods We conducted a comprehensive analysis using data extracted from the ClinicalTrials.gov database. A total of 1,441 trials were identified and categorized based on their completion and publication status. We examined various trial characteristics, including participant demographics, enrollment size, study design, and funding sources. Statistical regression models were employed to identify predictors of trial discontinuation and nonpublication.

Results Among the identified trials, 1,092 (75.8%) were completed, while 349 (24.2%) were discontinued. Of the completed trials, 641 (44.5%) were published. Larger enrollment sizes and multi-center designs significantly reduced the likelihood of discontinuation (Odds Ratio [OR] = 0.215; p < 0.001) and nonpublication (OR = 0.481; p < 0.001).

Conclusions The high rates of discontinuation and nonpublication in glioma trials underscore the need for improved research methodologies. Focusing on larger, multi-center collaborations could enhance trial completion and publication rates, ultimately benefiting glioma research and patient outcomes.

Authors/Disclosures
Ahmed Negida, MD, PhD (Virginia Commonwealth University) PRESENTER	Dr. Negida has nothing to disclose.
Yusra Arafeh, MD	Dr. Arafeh has nothing to disclose.
Asmaa Z. Zakria (Al-Azhar university)	Dr. Zakria has nothing to disclose.
Nada G Hamam, MBBS	Ms. G Hamam has nothing to disclose.
Amr Hassan, MD	Dr. Hassan has nothing to disclose.
Rnad Alajarmeh, MD	Dr. Alajarmeh has nothing to disclose.
Mohamed Abed, MBBS	Dr. Abed has nothing to disclose.
Bashar Z. Alsalhen	Mr. Alsalhen has nothing to disclose.

��ɫ��

��ɫ��